Heart Aging Tied to Loss of Ets2 Gene Regulator in Blood Vessel Cells
Scientists discover a super-enhancer controlling Ets2 in cardiac endothelial cells, linking its decline to fibrosis and accelerated heart aging.
Summary
Researchers identified a super-enhancer (Ets2-SE) that controls expression of the transcription factor Ets2 in cardiac endothelial cells. When Ets2 levels fall — as naturally occurs with aging — endothelial cells undergo a harmful transformation called endothelial-to-mesenchymal transition (EndoMT), triggering fibrosis and heart dysfunction. Mouse models lacking Ets2-SE or endothelial Ets2 showed accelerated cardiac aging and worsened outcomes after heart attack. Mechanistically, Ets2 normally keeps endothelial cells healthy by activating TIE1; its loss also triggers cellular senescence and a pro-inflammatory secretory state partly driven by Serpine1, compounding cardiac damage. The findings point to Ets2 and TIE1 as promising therapeutic targets against cardiovascular aging.
Detailed Summary
Cardiac aging involves progressive endothelial dysfunction, fibrosis, and declining heart function — but the molecular regulators orchestrating these changes remain incompletely understood. This study addresses a critical gap by examining how epigenetic regulation of the transcription factor Ets2 contributes to age-related cardiac pathology.
The research team used single-nucleus RNA sequencing (snRNA-Seq) in mice lacking a super-enhancer region (Ets2-SE) that normally drives Ets2 expression in the heart. They found that Ets2 levels decline with age specifically in cardiac endothelial cells, and that loss of the Ets2-SE accelerated this decline across cardiac tissue, producing advanced aging phenotypes including increased fibrosis and impaired cardiac function.
To isolate the endothelial-specific role, the team generated endothelial cell-specific Ets2 knockout (ECKO) mice. These animals showed exacerbated cardiac fibrosis and dysfunction both with normal aging and following myocardial infarction. In human umbilical vein endothelial cells, silencing ETS2 promoted endothelial-to-mesenchymal transition (EndoMT) — a process where endothelial cells lose their identity and adopt fibroblast-like, scar-forming behavior — by suppressing the endothelial marker gene TIE1 at the transcriptional level.
Ets2 loss also triggered cellular senescence and activated the senescence-associated secretory phenotype (SASP), with Serpine1 identified as a key downstream mediator amplifying myocardial fibrosis. Together, these mechanisms form a cascade in which epigenetic silencing of Ets2 drives endothelial aging, EndoMT, and ultimately structural heart disease.
The study's main caveat is that mechanistic findings rely heavily on mouse models and in vitro human cell lines, so direct translation to human cardiac aging requires further clinical investigation. Nonetheless, Ets2, TIE1, and Serpine1 emerge as compelling targets for future anti-aging cardiovascular therapies.
Key Findings
- A super-enhancer (Ets2-SE) governs Ets2 expression in cardiac endothelial cells; its loss accelerates heart aging.
- Ets2 deficiency promotes EndoMT by transcriptionally suppressing the endothelial marker gene TIE1.
- Endothelial-specific Ets2 knockout mice show worsened cardiac fibrosis and dysfunction after aging and heart attack.
- Ets2 loss triggers endothelial cell senescence and SASP, with Serpine1 driving downstream myocardial fibrosis.
- snRNA-Seq confirmed Ets2 downregulation in endothelial cells correlates with EndoMT activation in aged hearts.
Methodology
The study combined single-nucleus RNA sequencing (snRNA-Seq) in Ets2-SE-deficient mice with endothelial cell-specific Ets2 knockout mouse models to dissect cell-type-specific roles. In vitro validation used ETS2-silenced human umbilical vein endothelial cells to confirm mechanistic findings. Myocardial infarction models were used to assess disease-relevant functional outcomes.
Study Limitations
Key mechanistic findings are based on mouse genetic models and in vitro human cell lines, limiting direct extrapolation to human cardiac aging. The study does not yet identify pharmacological strategies to restore Ets2-SE activity, and the precise upstream triggers causing age-related Ets2-SE silencing remain unclear.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: